Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists
1–10 of 128 posts
Re: Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists
#2Kind of makes sense that stopping taking a drug that reduces heart attack and stroke risk leads to a return to the higher risk of before.
Re: Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists
#3Kind of a useless analysis if it doesn't compare the risk after stopping GLP-1s to the risk of NEVER taking GLP-1s in the first place.
We probably don't know the numbers yet, but one can easily envision a scenario like: risk of CE without GLP-1 weight loss: 20%. Risk after taking GLP-1s for 2 years: 10%. Risk after stopping GLP-1s: 12%. "Your heart attack chance goes up 20% after stopping GLP-1s!!!"
Re: Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists
#4This is a very odd phrasing that makes it seem like heart attack and stroke risk are higher for those who stop taking the drug than those who never took the drug. Moreover, the effect of restarting taking the drug seems attributable to the study design. Those who took a break had higher risk at the end of the study than those who don’t. But those who took a break took the drug for less total time than those who took it for the entire study.
You could characterize these same facts in the opposite way. GLP-1s don’t permanently change your body. They provide benefits while taking them but quickly clear out of your system when you stop taking them. Arguably, that’s a good thing in a drug.
Re: Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists
#5How much of this could attributed to simply having less artificial hormonal support for not overeating after discontinuing treatment, and falling back into old habits? I’d love to see more research focused on these mechanisms.
Re: Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists
#6In veterans with T2 diabetes:
> To find out what happens when people stop taking GLP-1s, Al-Aly’s team of researchers tracked the health of more than 333,000 United States veterans with type 2 diabetes for three years.
Re: Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists
#7This is a very odd phrasing that makes it seem like heart attack and stroke risk are higher for those who stop taking the drug than those who never took the drug. Moreover, the effect of restarting taking the drug seems attributable to the study design. Those who took a break had higher risk at the end of the study than those who don’t. But those who took a break took the drug for less total time than those who took…
>This is a very odd phrasing that makes it seem like heart attack and stroke risk are higher for those who stop taking the drug than those who never took the drug.
That does appear to be the case, according to the study.
Re: Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists
#8Studies get worse every year.
Re: Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists
#9This is a very odd phrasing that makes it seem like heart attack and stroke risk are higher for those who stop taking the drug than those who never took the drug. Moreover, the effect of restarting taking the drug seems attributable to the study design. Those who took a break had higher risk at the end of the study than those who don’t. But those who took a break took the drug for less total time than those who took…
>This is a very odd phrasing that makes it seem like heart attack and stroke risk are higher for those who stop taking the drug than those who never took the drug. That does appear to be the case, according to the study.
The conclusion of the study says:
> This study showed that discontinuing and interrupting GLP-1RA treatment could erode and might reverse the cardiovascular benefits of the drug in a duration dependent manner, increasing the risk of cardiovascular events.
emphasis mine
Re: Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists
#10We finally found the first morbidity signal of GLP-1s (or lack thereof).
These are life changing drugs, but like plastic we'll see their effects in force within this generation:
> The longer time spent off GLP-1s, the greater the risk of major cardiovascular events—up to 22 percent for those who abstained for two years.